The effect of the cholinesterase inhibitor donepezil on organic and functional deficits related to growth hormone deficiency in old age.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001315-22-AT

Enrollment

Registered

2006-01-18

Start date

2006-03-09

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

We plan to study healthy aging subjects.

Interventions

Trade Name: Aricept Product Name: Aricept Product Code: Donepezil Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Gastroenteral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy aging women and men aged 70 to 75 years. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Sick sinus syndrome, atrioventricular block, sinuatrial block Asthma brochiale, COPD Gastric or duodenal ulcers Urinary obstruction Severe renal or hepatic impairment Known hypersensitivity against the investigational drug Medication with beta-blockers, cholinomemetica or NSAIDs

Design outcomes

Primary

Measure	Time frame
Main Objective: The main objective of the trial is to assess if the application of the cholinesterase inhibitor donezpezil results in an increase secretion of growth hormone and IGF-1 and if this effect is sustained.;Secondary Objective: Seconary objectives are to investigate effects of an increased growth hormone/IGF-1 secretion on selected age related alterations of body composition and functional decline (e.g. bone mineral density, muscle function, fat mass, serum lipids, cognitive function, depression).;Primary end point(s): IGF-1 serum levels	—

Measure

Time frame

Main Objective: The main objective of the trial is to assess if the application of the cholinesterase inhibitor donezpezil results in an increase secretion of growth hormone and IGF-1 and if this effect is sustained.;Secondary Objective: Seconary objectives are to investigate effects of an increased growth hormone/IGF-1 secretion on selected age related alterations of body composition and functional decline (e.g. bone mineral density, muscle function, fat mass, serum lipids, cognitive function, depression).;Primary end point(s): IGF-1 serum levels

—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026